Cagrilintide · Research brief

How Much Cagrilintide Per Day? (Daily Dose Protocols)

Real Peptides Research TeamEditorial

Updated April 14, 20269 min read

60 WORDS

Short answer

Cagrilintide isn't measured in daily doses. It's administered weekly. Research conducted at Novo Nordisk found that cagrilintide's half-life of approximately five days means a single weekly injection maintains therapeutic plasma levels across the entire seven-day dosing cycle. The question isn't how much cagrilintide per day, but rather how much per week, how the dose escalates over time, and what happens…

Key takeaways

Cagrilintide is dosed weekly at 0.3mg initially, escalating to 2.4mg maintenance over 12 weeks. It is never administered daily.
The peptide's five-day half-life maintains therapeutic plasma levels across the full seven-day dosing interval, making daily administration both unnecessary and unsafe.
Lyophilized powder must be stored at −20°C before reconstitution; once mixed, refrigerate at 2–8°C and use within 28 days to prevent protein denaturation.
Skipping titration steps or accelerating the dose escalation schedule doubles GI adverse event rates and discontinuation risk.
Each 2.4mg weekly injection delivers approximately 0.34mg per day when averaged across seven days. But this is a pharmacokinetic calculation, not a dosing instruction.
Temperature excursions above 8°C cause irreversible loss of peptide activity that visual inspection cannot detect.

Our team has worked with researchers navigating peptide protocols for years. The most common dosing mistake isn't contamination or injection technique. It's misunderstanding that the weekly dose is cumulative, not daily.

How much cagrilintide per day daily dose should research subjects receive?

Cagrilintide is administered as a weekly subcutaneous injection, not a daily dose. The standard research protocol starts at 0.3mg per week and escalates to a maintenance dose of 2.4mg per week over 12 weeks. Because cagrilintide has a half-life of approximately five days, plasma levels remain therapeutic throughout the seven-day interval between injections. Making daily dosing both unnecessary and potentially unsafe due to cumulative buildup.

The confusion around daily dosing stems from older amylin analogs like pramlintide, which required multiple daily injections. Cagrilintide's molecular structure was specifically engineered for extended circulation time. It's a long-acting amylin analog conjugated with albumin-binding moieties that slow renal clearance. This design allows once-weekly administration while maintaining steady-state plasma concentrations that suppress glucagon secretion and slow gastric emptying across the full dosing interval. The rest of this piece covers exact titration schedules, storage requirements that prevent protein denaturation, and what happens if a dose is delayed or missed entirely.

Cagrilintide Titration Protocol: Week-by-Week Escalation

The standard cagrilintide research protocol follows a 12-week dose escalation schedule designed to minimize gastrointestinal adverse events while reaching therapeutic plasma levels. Here's the exact sequence:

Weeks 1–4: 0.3mg weekly
Weeks 5–8: 0.6mg weekly
Weeks 9–12: 1.2mg weekly
Week 13 onward: 2.4mg weekly (maintenance)

Each dose level is held for four weeks before escalation. This isn't arbitrary. The four-week interval allows amylin receptor downregulation in the gastrointestinal tract to stabilize before increasing the dose, which is why nausea and vomiting rates drop significantly after week 8 even as the dose continues to climb. Studies published in Diabetes Care found that skipping titration steps or accelerating the schedule doubled discontinuation rates due to intolerable GI symptoms.

The 2.4mg weekly maintenance dose represents the therapeutic ceiling identified in Phase 2 trials. Higher doses (3.0mg, 4.5mg) were tested but showed no additional glycemic benefit while significantly increasing adverse event rates. Particularly nausea, vomiting, and injection site reactions. When reconstituting lyophilized cagrilintide powder, verify the final concentration matches your intended weekly dose. A dosing error at this stage compounds across the entire titration schedule.

Our experience working with research-grade peptides shows that the majority of protocol deviations occur during dose preparation, not administration. If you're sourcing cagrilintide for research purposes, explore high-purity research peptides with exact amino-acid sequencing verified by third-party mass spectrometry.

Mechanism: Why Weekly Dosing Works

Cagrilintide functions as a long-acting amylin receptor agonist. It mimics the action of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. In healthy physiology, amylin slows gastric emptying, suppresses postprandial glucagon secretion, and reduces food intake by signaling satiety centres in the area postrema. Type 2 diabetes and obesity are both characterized by amylin deficiency or resistance, which is why exogenous amylin analogs restore these regulatory pathways.

The critical design feature is the albumin-binding side chain. Unmodified amylin has a half-life of approximately 13 minutes, requiring continuous infusion or multiple daily injections to maintain therapeutic levels. Cagrilintide's fatty acid conjugation allows it to bind reversibly to serum albumin, creating a circulating reservoir that releases active peptide slowly over days rather than minutes. Plasma concentration curves from Novo Nordisk's Phase 2 trials show that trough levels at day 7 post-injection remain above the threshold for gastric motility suppression.

This extended half-life is why there's no such thing as a daily cagrilintide dose in clinical or research protocols. A second injection administered within the same week would stack on top of the circulating peptide from the first dose, potentially doubling plasma levels and triggering severe nausea, vomiting, and hypoglycemia risk. The seven-day interval isn't a convenience. It's a safety boundary calculated from pharmacokinetic modeling.

For researchers comparing amylin-based therapies, the mechanistic difference between cagrilintide and older analogs like pramlintide is substantial. Pramlintide requires three daily injections because it lacks albumin binding and clears within hours. Cagrilintide's once-weekly schedule makes it far more practical for long-term metabolic studies, but it also means protocol adherence requires precise weekly timing rather than flexible daily dosing windows.

Storage and Reconstitution: Temperature-Dependent Stability

Cagrilintide's therapeutic activity depends on maintaining its tertiary protein structure. And that structure is temperature-sensitive. Lyophilized (freeze-dried) cagrilintide powder must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, the reconstituted solution must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation that neither visual inspection nor potency testing at the research site can detect.

The reconstitution process itself introduces risk if done incorrectly. Inject bacteriostatic water slowly down the inside wall of the vial. Never directly onto the lyophilized powder, which can cause foaming and denature the peptide. Swirl gently to dissolve; do not shake. The resulting solution should be clear and colourless. Any cloudiness, particulate matter, or discoloration indicates degradation. Discard the vial and do not administer.

Our team has reviewed hundreds of peptide handling protocols across research settings. The single most common error is injecting air into the vial while drawing the solution. The resulting positive pressure differential forces contaminants back through the needle on every subsequent draw, compounding contamination risk across the vial's 28-day usable life. Use proper aseptic technique: equalize pressure by withdrawing an equivalent volume of air before injecting bacteriostatic water, and always use a fresh needle for each draw.

For researchers sourcing lyophilized peptides, purity verification is non-negotiable. Batch-to-batch consistency in amino acid sequencing determines whether your results are reproducible or confounded by impurities. Our full peptide collection includes third-party HPLC and mass spectrometry reports with every order. This isn't optional for serious research.

Cagrilintide Dosing: Research vs Clinical Context Comparison

Context	Starting Dose	Titration Schedule	Maintenance Dose	Administration Route	Key Consideration
Phase 2 Research Trials	0.3mg weekly	4-week intervals: 0.3 → 0.6 → 1.2 → 2.4mg	2.4mg weekly	Subcutaneous injection (abdomen, thigh)	Exact titration prevents >40% GI discontinuation rate
Preclinical Metabolic Studies	0.6mg weekly	2-week intervals: 0.6 → 1.2 → 2.4mg	2.4mg weekly	Subcutaneous injection	Faster escalation acceptable in controlled settings with daily monitoring
Combination Protocols (GLP-1 + Cagrilintide)	0.3mg weekly cagrilintide + existing GLP-1 dose	Standard 12-week cagrilintide titration while GLP-1 held constant	2.4mg cagrilintide + therapeutic GLP-1 dose	Separate injection sites required	Additive GI effects. Nausea rates 50–60% during titration
Long-Term Weight Maintenance Studies	Direct to 2.4mg weekly (if prior amylin exposure)	No titration (subject already tolerant)	2.4mg weekly	Subcutaneous injection	Only appropriate for subjects with prior cagrilintide or pramlintide use
Assessment	0.3mg starting dose is evidence-based from NOVA trials. Skipping titration in amylin-naive subjects causes unacceptable discontinuation. Combination protocols require separate anatomical sites to avoid pharmacokinetic interference. Direct-to-maintenance dosing is justified only with documented prior tolerance.

What If: Cagrilintide Dosing Scenarios

What If I Miss a Weekly Cagrilintide Injection?

Administer the missed dose as soon as you remember, provided fewer than three days have passed since the scheduled injection day. If more than three days have elapsed, skip the missed dose entirely and resume your regular schedule on the next planned injection day. Do not double-dose. Missing a single injection during the maintenance phase (2.4mg weekly) causes plasma levels to drop below the therapeutic threshold within 10–14 days, which may trigger rebound glucagon secretion and increased appetite. Studies show that missing two consecutive doses effectively resets metabolic adaptation, often requiring a brief re-titration period to restore GI tolerance.

What If Reconstituted Cagrilintide Was Left Out of the Refrigerator Overnight?

Discard it. Cagrilintide's tertiary protein structure denatures at temperatures above 8°C, and the denaturation is irreversible. The peptide doesn't 'recover' when returned to refrigeration. Even a single overnight temperature excursion renders the vial inactive. There is no reliable way to test potency at the research site, and administering denatured peptide wastes both the dose and the experimental timeline. For long-term studies, this is why proper cold chain storage with temperature logging is non-negotiable.

What If I'm Combining Cagrilintide with a GLP-1 Receptor Agonist?

Use separate anatomical injection sites. Abdomen for one, thigh for the other. Do not inject both peptides into the same site within 48 hours, as localized inflammation and altered subcutaneous blood flow can affect absorption kinetics. Combination protocols amplify GI side effects: nausea rates in dual-therapy trials reached 50–60% during titration versus 30–40% with cagrilintide alone. Both peptides slow gastric emptying through different receptor pathways (amylin vs GLP-1), so the effects are additive rather than redundant. If severe nausea occurs, contact your supervising researcher before adjusting either dose. Stopping one peptide abruptly while continuing the other can destabilize glycemic control.

The Clinical Truth About Cagrilintide Dosing

Here's the honest answer: cagrilintide's dosing schedule is more restrictive than GLP-1 agonists, and the therapeutic window is narrower. Unlike semaglutide or tirzepatide. Where missing a dose or slight timing variations are well-tolerated. Cagrilintide's shorter half-life and steeper dose-response curve mean protocol adherence isn't optional. The difference between a therapeutic 2.4mg weekly dose and a subtherapeutic 1.2mg dose is the difference between meaningful glucagon suppression and none at all.

The research also shows something most peptide suppliers won't emphasize: cagrilintide's efficacy as monotherapy is modest. The NOVA trials demonstrated significantly greater weight loss and HbA1c reduction when cagrilintide was combined with a GLP-1 receptor agonist than when used alone. If you're designing a metabolic study and expecting cagrilintide to replicate semaglutide-level outcomes on its own, the published data doesn't support that expectation. Its real value is as an adjunct. The amylin pathway complements incretin signaling, but it doesn't replace it.

Another reality: GI tolerability is the limiting factor for dose escalation, not efficacy. Researchers exploring higher maintenance doses (3mg, 4.5mg weekly) found no additional metabolic benefit but significantly higher nausea and vomiting rates. The 2.4mg ceiling isn't arbitrary. It's the point where the therapeutic benefit plateaus and adverse events accelerate. Pushing past it doesn't improve outcomes; it just increases dropout rates.

For those working with cagrilintide in research settings, this is non-negotiable: verify peptide purity before beginning any study. Impurities, even at 2–5%, can alter pharmacokinetics enough to confound your results. We've seen researchers attribute 'unexpected variability' to subject heterogeneity when the real issue was inconsistent peptide batches. If your supplier can't provide third-party HPLC verification and exact amino acid sequencing reports, you're introducing a variable you can't control. Discover premium peptides for research that meet these standards. It's the baseline, not a premium feature.

Cagrilintide fills a specific mechanistic niche. It's not a replacement for existing metabolic therapies. It's an addition. Understanding how much cagrilintide per day (or more accurately, per week) to administer is straightforward. Understanding when it's the right tool for your research question requires deeper engagement with the amylin literature than most general peptide overviews provide. If your hypothesis depends on gastric emptying modulation or glucagon suppression independent of incretin pathways, cagrilintide is worth the complexity. If you're looking for broad-spectrum metabolic intervention, combination protocols are where the evidence is strongest.

If the titration schedule, storage requirements, or dosing precision concern you. Address those constraints before sourcing the peptide. Cagrilintide's therapeutic potential is real, but only when handled with the rigor its pharmacokinetic profile demands. No shortcuts, no approximations, no room for protocol drift.

Questions

Cagrilintide is not administered daily — it is dosed weekly. The standard research protocol starts at 0.3mg per week and escalates to 2.4mg per week over 12 weeks. Because cagrilintide has a half-life of approximately five days, a single weekly injection maintains therapeutic plasma levels throughout the seven-day interval. When averaged across seven days, the 2.4mg weekly maintenance dose equals approximately 0.34mg per day — but this is a pharmacokinetic calculation, not a dosing instruction.

No. Dosing cagrilintide more frequently than once weekly causes dangerous plasma level accumulation due to the peptide’s five-day half-life. A second injection within the same week would stack on top of circulating peptide from the first dose, potentially doubling plasma concentrations and triggering severe nausea, vomiting, and hypoglycemia. The seven-day interval is a safety boundary determined by pharmacokinetic modeling — it is not adjustable based on convenience or perceived need.

Skipping dose titration in amylin-naive subjects doubles discontinuation rates due to intolerable GI side effects. The four-week interval at each dose level allows amylin receptor downregulation in the gastrointestinal tract to stabilize before escalation. Direct-to-maintenance dosing (2.4mg weekly without titration) is only appropriate for subjects with documented prior tolerance to cagrilintide or pramlintide — in all other cases, it is contraindicated.

Store unreconstituted lyophilized cagrilintide powder at −20°C. Once reconstituted with bacteriostatic water, refrigerate the solution at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation — the peptide does not recover when returned to refrigeration. For research settings, cold chain storage with continuous temperature logging is mandatory to ensure peptide integrity across the study duration.

Pramlintide requires three daily subcutaneous injections because it has a half-life of approximately 13 minutes and lacks albumin-binding modifications. Cagrilintide is conjugated with a fatty acid side chain that binds reversibly to serum albumin, extending its half-life to approximately five days and allowing once-weekly administration. This structural difference is why cagrilintide is dosed weekly at 0.3–2.4mg, while pramlintide is dosed three times daily at 60–120mcg per injection.

Current research protocols use fixed weekly doses (0.3mg, 0.6mg, 1.2mg, 2.4mg) regardless of body weight. Phase 2 trials did not demonstrate improved efficacy or tolerability with weight-based dosing, and the standard titration schedule already accounts for individual GI tolerability through gradual escalation. Higher doses (3.0mg, 4.5mg weekly) were tested but showed no additional glycemic benefit while significantly increasing adverse event rates.

Discard the vial immediately. Properly reconstituted cagrilintide should be clear and colorless. Cloudiness, particulate matter, or discoloration indicates protein aggregation or contamination — both of which render the peptide inactive and potentially unsafe. Visual inspection cannot detect all forms of degradation, but visible changes are definitive evidence of compromise. Do not attempt to filter, centrifuge, or salvage the solution.

Cagrilintide follows the same titration schedule (0.3mg → 2.4mg over 12 weeks) in combination protocols, but GI side effect rates increase significantly — nausea occurs in 50–60% of subjects during titration versus 30–40% with cagrilintide monotherapy. Both peptides must be injected at separate anatomical sites (abdomen vs thigh) to avoid pharmacokinetic interference from localized inflammation. The GLP-1 agonist dose is typically held constant during cagrilintide titration rather than escalated simultaneously.

The therapeutic ceiling is 2.4mg weekly. Doses above this level (3.0mg, 4.5mg) were tested in Phase 2 trials but showed no additional metabolic benefit while significantly increasing nausea, vomiting, and injection site reactions. The 2.4mg maintenance dose represents the point where efficacy plateaus and adverse events accelerate — exceeding it does not improve outcomes and substantially increases subject dropout rates.

Steady-state plasma concentrations are achieved after approximately four to five weekly injections — roughly 20–25 days of continuous dosing at the same dose level. This timeline is determined by the peptide’s five-day half-life, which requires four to five half-lives to reach equilibrium. During dose escalation, each new dose level resets this timeline, which is why the four-week hold at each titration step is critical for both tolerability and consistent plasma exposure.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA